alexa Development Of Sphingosine Kinase Inhibitors For Cancer Therapy | 22317
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Cell & Gene Therapy

Zuping Xia
ScientificTracks Abstracts: J Stem Cell Res Ther
DOI: 10.4172/2157-7633.S1.007
Abstract
It has become evident that cancers have complicated signaling survival pathways. Currently, the most effective treatment for cancer diseases commonly requires target multiple pathways. Sphingosine Kinase (SK) is one of the critical enzymes in spingolipid biosynthesis. So far there are two isoforms of SK discovered, SK1 and SK2. Although the similarity and differences between these two isoforms are still not quite clear, the convincing evidences have been shown that SK, especially SK1, is related to human diseases, such as cancer. SK1 has been revealed as an oncogene that is among the most commonly overexpressed oncogenes in human cancers. Furthermore, compared to the drug sensitive cancer cell lines, over-expression of SK has also been found to contribute to the drug resistance in many cancer chemotherapies. The cumulated evidence has strongly supported that SK is one of the potential druggable targets for cancer therapy. We have identified a few of SK inhibitors by screening a small molecule library. One of them stood out upon testing, namely 4-[4-(4-chlorophenyl)thiazol-2-ylamino] phenol (SKI-II). However, we found that SKI-II has a narrow therapeutic window, poor bioavailability and relatively unstable. In order to optimize this lead compound, we used three approaches and synthesized a series of SKI-II analogs. We have done primary evaluation of these compounds which will guide our further improvement of SK inhibitors for cancer therapy.
Biography
Zuping Xia obtained his PhD in Pharmaceutical Sciences (Medicinal Chemistry) from University of Alberta mentored by both Dr. Leonard Wiebe and Dr. Edward Knaus. He has completed his Postdoctoral training in Dr. Kenneth Brown Lab at Ohio University and in Dr. Charles Smith Lab at Penn State University. His major interests are in the drug discovery and ADME/PK studies. Presently, he is a Research Associate Professor and Director of NMR core at College of Pharmacy, Washington State University.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7